August 2012
-
Marinomed Biotech has announced that a Phase 3 trial of Budesolv budesonide nasal spray has met its primary endpoint. Without providing any specific data, the company said that, “The top line results are now available… Read more . . .
-
Satsuma Pharmaceuticals said that it has raised $62 million in Series B financing that will be used for Phase 3 development of its STS101 intranasal dry powder dihydroergotamine (DHE) for the treatment of migraines. Satsuma… Read more . . .
-
Inhaler testing equipment company Copley Scientific announced that it has acquired Novi Systems, which manufactures inhaler testing automation solutions, including the Ictus automated Andersen cascade impactor, the Vertus shake, fire and flow control systems, and… Read more . . .
-
Boehringer Ingelheim said recently that it has completed a €105 million expansion of its facilities in Dortmund and Ingelheim, Germany to increase manufacturing capacity for its Respimat soft mist inhaler. The company said that the… Read more . . .
-
Neurelis, which submitted an NDA for its Valtoco diazepam nasal spray in September 2018, has announced the appointments of a number of senior management personnel in anticipation of a launch. The appointments announced took place… Read more . . .
-
Novus Therapeutics said that two Phase 1 trials of its OP0201 intranasal MDI, which is in development for otitis media, both met their primary endpoints. In one of the studies, healthy adults received either a… Read more . . .
-
The FDA has announced the final approval of Teva’s ANDA for a generic naloxone hydrochloride nasal spray. According to the announcement, the agency tentatively approved the ANDA in June 2018. Opiant Pharmaceutical’s Narcan nasal spray… Read more . . .
-
Akorn announced that the FDA has approved an ANDA for fluticasone propionate nasal spray submitted by Hi Tech Pharmacal, which was acquired by Akorn in 2014. The nasal spray is a generic of GSK’s Flonase,… Read more . . .
-
What is dynamic powder testing and why is it valuable for DPI development? Read more . . .
-
According to Hovione Technology, the company has acquired global development and commercialization rights to the Papillon multi-use dry powder inhaler from its inventor, Klaus-Dieter Beller. The blister-based DPI is reusable and formed from a single… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.